Xilio Therapeutics has announced the promotion of Martin Huber (photo) to president. He will retain his title of head of research and development. In addition, Paul Clancy has been elected as chair of the board of directors and Robert Ross has been appointed as a member of the board. Clancy has served on Xilio’s board of directors since July 2020 and succeeds Dan Lynch, who previously served as chair and will transition to serving as a strategic advisor to the company. Ross is CEO of Surface Oncology.

“I am delighted to announce the promotion of Marty to president of Xilio,” said René Russo, CEO of Xilio. “Marty’s R&D and operational leadership will be instrumental to the continued growth and evolution of the company as we seek to advance our tumor-selective immuno-oncology programs.”

Harpoon Therapeutics has named Banmeet Anand senior vice president of translational medicine. Anand was most recently head of nonclinical development/clinical pharmacology at Molecular Templates. He previously served in multiple leadership and scientific roles at NantKwest, Astellas (Agensys) and Genentech.

Lindsay Androski has been named to the board of directors of Eloxx Pharmaceuticals. Androski is a member of the founding team at Roivant Sciences and is the founder, president and CEO of Roivant Social Ventures, a social impact organization that makes early-stage investments and incubates biotech companies focused on improving healthcare access and outcomes for underserved groups.

TScan Therapeutics has named Debora Barton chief medical officer. She was most recently CMO at Carisma Therapeutics, and previously served as senior vice president, head of clinical and head of safety at Iovance Biotherapeutics.

Robert Denison has been appointed CEO and a member of the board of digital health company Congenica. He joined Congenica as chief information officer in September 2019.

Late-stage clinical biotech Tevogen Bio has named Neal Flomenberg chief scientific officer and global head of R&D. Flomenberg most recently served as professor and chairman of the department of medical oncology and deputy director of Sidney Kimmel Cancer Center of Thomas Jefferson University & Hospital.

Robert B. Geller has been appointed chief medical officer of Aravive. He has held positions in medical affairs and clinical development at Alexion, Heron Therapeutics and most recently as senior vice president of medical affairs at Coherus Biosciences.

Clinical-stage Syndax Pharmaceuticals has announced the appointment of Keith A. Goldan as CFO. Goldan, who brings nearly 30 years of leadership and operational experience in biopharma and medical technology companies, most recently served as CFO at Optinose.

Adagio Therapeutics has named David Hering permanent CEO, succeeding Tillman Gerngross, who announced his resignation in February. Appointed Adagio’s chief operating officer in July 2021, Hering had been serving as interim CEO since Gerngross’s announcement. Before joining the company, he was head of Pfizer’s mRNA global franchise, helping to launch the pharma’s COVID-19 vaccine.

Michael Kalb has resigned as senior vice president and CFO of Amarin to pursue other interests. He is succeeded by Thomas Reilly, who most recently served as CFO of Cara Therapeutics.

Cambridge, UK–based synthetic biology company Evonetix has named Colin McCracken CEO. McCracken brings over 20 years’ experience in commercial and business development roles, most recently serving as senior vice president and chief commercial officer at Fluidigm.

Richard Nieman has been appointed chief medical officer of Lyra Therapeutics. A pulmonologist with deep pharmaceutical medicine experience, Nieman has previously served as senior vice president and worldwide medical head of immunology at Bristol Myers Squibb, global medical officer and head of medical at Teva, and head of Asia Pacific medical at Bayer.

Chris O’Brien has been appointed chief medical officer of clinical-stage Kinaset Therapeutics. Most recently, O’Brien served as Janssen Pharmaceuticals’ head of pulmonary clinical development, head of GI clinical development and as a compound development team leader. Before that, he was vice president of respiratory clinical development at Teva Pharmaceuticals.

Next-generation sequencing company Burning Rock Biotech has announced the resignation of Jing Rong as a board director and the appointment of Licen Lisa Xu as an independent director to the board. Xu has over 15 years of experience in research and development of life science and biomedical products. She is currently chief commercial officer of FlashDx and an independent board member of Ribbon Biolab, and previously served as a vice president of strategic product management and lifecycle management at Roche Diagnostics.

Milan-based gene therapy company Genespire has announced the appointment of Sabah Sallah as chief medical officer. A board-certified hematologist with over 25 years’ experience in clinical, commercial and academic roles, Sallah joins the company from Freeline Therapeutics, where he served as senior vice president, gene therapy, translational medicine and hematology.